standard adjuvant chemotherapy + moxifloxacin

Standard adjuvant chemotherapy + moxifloxacin is a combination treatment regimen being evaluated in a Phase III clinical trial (NCT05115630) led by Sun Yat-sen University for patients with operable breast cancer. The regimen incorporates standard-of-care adjuvant chemotherapy—which may include docetaxel, nab-paclitaxel, cyclophosphamide, or doxorubicin—supplemented with the fluoroquinolone antibiotic moxifloxacin. The study investigates whether the addition of moxifloxacin can improve disease-free survival (DFS), potentially by modulating the microbiome or through other non-canonical effects of the antibiotic in the context of breast cancer treatment.

Other names

Standard Adjuvant Chemotherapy Plus MoxifloxacinMoxifloxacin plus standard adjuvant chemotherapystandard adjuvant chemotherapy-Sun Yat-sen University-breast cancer